The role of intestinal dysbiosis in endothelial dysfunction evolution in patients with microvascular angina
Keywords:Dysbiosis, microvascular angina, lipopolysaccharides, zonulin
Purpose. Evaluation of circulating levels of lipopolysaccharide and zonulin in conjunction with markers of endothelial dysfunction, inflammation, and oxidative stress in patients with microvascular angina (MА). Material and methods. The study was carried out in a group of 58 patients with MA hospitalized in the Institute of Cardiology. The determination of circulating levels of 20 biomarkers was carried out in cooperation with the laboratory investigation center of Sapienza University (Italy). All functional and biochemical markers were also determined in 48 apparently healthy people (control group) with the values of which the markers of MA patients were compared. Results. Endothelial dysfunction in patients with MA excelled by increasing the thickness of the intima-media complex of the carotid artery by 41%, as well as by reducing of flow-mediated brachial artery dilatation (FMD) by 31,6%. The presence of dysbiosis was manifested by an 80% increase in the serum content of lipopolysaccharides (LPS) and by doubling of zonulin (1,8±0,3 vs 3,6±0,7 ng/ml). Endothelial dysfunction and dysbiosis evolved in association with oxidative stress activation estimated by means of 6 markers and increased serum content of 6 important pro-inflammatory markers (hsCRP, IL-6, TNF-α, etc.) Conclusions. 1. In patients with MA, elevated circulating levels of LPS and zonulin more than twice compared to the control value were found, which indicates the presence of intestinal dysbiosis. 2. LPS and zonulin correlate robustly with morphofunctional and biochemical markers of endothelial dysfunction, as well as with markers of its main pathogenetic factors, inflammation and oxidative stress.
Sinha A, Rahman H, Perera D. Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management. Cardiovasc Endocrinol Metabol, 2020, 10(1):22-30.
Villano A, Lanza GA, Crea F. Microvascular angina: prevalence, pathophysiology and therapy. J Cardiovasc Med (Hagerstown), 2018, 19 Suppl 1:e36-39.
Chen C, Wei J, AlBadri A et al. Coronary Microvascular DysfunctionEpidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy. Circ J, 2016, 81:3-11.
Rahman H, Ryan M, Lumley M et al. Coronary microvascular dysfunction is associated with myocardial ischemia and abnormal coronary perfusion during exercise. Circulation, 2019, 140:1805–1816.
Rahman H, Demir OM, Khan F et al. Physiological stratification of patients with angina due to coronary microvascular dysfunction. J Am Coll Cardiol, 2020, 75:2538–2549.
Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J, 2018;39:3439–50.
Sara JD, Widmer RJ, Matsuzawa Y et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv, 2015, 8:1445–1453.
Cannon RO, III, Epstein SE. “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol, 1988, 61:1338–1343.
Duncker DJ, Koller A, Merkus D et al. Regulation of coronary blood flow in health and ischemic heart disease. Prog Cardiovasc Dis, 2015, 57:409–422.
Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol, 2018, 72:2625–2641.
Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation, 2011, 124:1774–1782.
Widmer RJ, Lerman LO, Lerman A. The Rho(ad)-kinase for individualized treatment of vasospastic angina. Eur Heart J, 2018, 11:960-962.
Sucato V, Corrado E, Manno G et al. Biomarkers of Coronary Microvascular Dysfunction in Patients With Microvascular Angina: A Narrative Review. Angiology, 2022,73(5): 395-406.
Grylls A, Seidler K, Neil J. Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomed Pharmacother, 2021, 137:1113-34.
Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol, 2004, 24:2227-36.
Loffredo L, Ettorre E, Zicari AM et al. Oxidative Stress and Gut-Derived Lipopolysaccharides in Neurodegenerative Disease: Role of NOX2. Oxid Med Cell Longev. 2020, 86:30275.
Loffredo L, Ivanov V, Ciobanu N et al. Is There an Association Between Atherosclerotic Burden, Oxidative Stress, and Gut-Derived Lipopolysaccharides? Antioxid Redox Signal. 2020, 33(11): 8109.
Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci, 2018, 14(3): 701-706.
Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int, 2018, S0197-0186(18): 30198-30190.
Jonsson AL, Backhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol. 2017;14: 79–87.
Britoalves JL, deSouza EL, deCamposCrus J et al. Gut dysbiosis in arterial hypertension: a candidate therapeutic target for blood pressure management. In: Microbiome and metabolome in diagnosis, therapy and other strategic applications, red. J.Faintuch and S.Faintuch, 2019, Copyright Elsevier, p.243-249.
Pastori D, Carnevale R, Nocella C et al. Gut‐Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. J Am Heart Assoc, 2017, 6(6):e005784.
Ong P, Camici PG, Beltrame JF et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol, 2018;250:16-20.
Green DJ, Jones H, Thijssen D, Atkinson G. Flow-Mediated Dilation and Cardiovascular Event Prediction Does Nitric Oxide Matter? Hypertension, 2011, 57:363-369.
Thijssen D, Bruno R, van Mil A et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. European Heart Journal, 2019, 40(30:534–2547.
McCully K. Flow-mediated dilation and cardiovascular disease. J Appl Physiol, 2012, 112: 1957–1958.
Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Annals of Internal Medicine. 1998, 128(4):262–269.
Hulthe J, Wikstrand J, Emanuelsson H et al. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke, 1997, 28(6):1189–1194.
Liu D, Du C, Shao W, Ma G. Diagnostic Role of Carotid Intima-Media Thickness for Coronary Artery Disease: A Meta-Analysis. Biomed Res Int. 2020: 9879463.
Masaki T, Sawamura T. Endothelin and endothelial dysfunction. Proc Jpn Acad Ser B Phys Biol Sci, 2006, 82(1): 17–24.
Sun HJ, Wu ZY, Nie XW, Bian JS. Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide. Front Pharmacol, 2020, 10:1568.
Hu Q, Ke X, Zhang T et al. Hydrogen sulfide improves vascular repair by promoting endothelial nitric oxide synthase-dependent mobilization of endothelial progenitor cells. J Hypertebs, 2019, 37(5):972-984.
Ajamian N. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS One, 2019, 14(1): e0210728.
Li J, Qin Y, Chem Y et al. Mechanisms of the lipopolysaccharide-induced inflammatory response in alveolar epithelial cell/macrophage co-culture. Exp Ther Med, 2020, 20(5):76.
Senatus L, MacLean M, Arivazhaga L. Inflammation Meets Metabolism: Roles for the Receptor for Advanced Glycation End Products Axis in Cardiovascular Disease. Immunometabolism, 2021, 3(3):e210024.
Munzel T, Camici G, Maack C et al. Impact of Oxidative Stress on the Heart and Vasculature Part 2 of a 3-Part Series. J Am Coll Cardiol, 2017, 70(2):212-229.
Stanisavljevic N, Wilson W. Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. Clinical Rheumatology, 2016, 35(10):2485-2493.
Copyright (c) 2023 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.